Changes in Blood Flow in MCA of Fetuses to Mothers Having Clinical Chorioamnionitis - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

March 5, 2006

Last Updated Date

November 29, 2006

Start Date ^†

October 2006

Current Primary Outcome Measures ^†

Original Primary Outcome Measures ^†

Change History

Complete list of historical versions of study NCT00299637 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

Original Secondary Outcome Measures ^†

Descriptive Information

Brief Title ^†

Changes in Blood Flow in MCA of Fetuses to Mothers Having Clinical Chorioamnionitis

Official Title ^†

Changes in Blood Flow in MCA of Fetuses to Mothers Having Clinical Chorioamnionitis During Labor Comparing to Fetuses to Healthy Mothers.

Brief Summary

This study will try to determine whether fetuses to mothers having clinical chorioamnionitis have changes in blood flow in middle cerebral artery.

Detailed Description

This study will try to determine whether fetuses to mothers having clinical chorioamnionitis have changes in blood flow in middle cerebral artery.

MCA flow parameters will be evaluated during labor of women with and wthout chorioamnionitis

Study Phase

Phase 0

Study Type ^†

Observational

Study Design ^†

Natural History, Cross-Sectional, Case Control, Prospective Study

Condition ^†

Chorioamnionitis

Intervention ^†

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Recruiting

Enrollment ^†

Estimated Completion Date

December 2007

Primary Completion Date

Eligibility Criteria ^†

Inclusion Criteria:

women giving birth week 37-42
healthy
one fetus

Exclusion Criteria:

more than one fetus
IUGR
illness or damage to fetus

Gender

Female

Ages

20 Years to 45 Years

Accepts Healthy Volunteers

Contacts ^††

Contact: david mankuta, MD

mankuta@yahoo.com

Location Countries ^†

Israel

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00299637

Responsible Party

Secondary IDs ^††

Study Sponsor ^†

Hadassah Medical Organization

Collaborators ^††

Investigators ^†

Study Chair:

David Mankuta, MD

Hadassah Medical Organization

Information Provided By

Hadassah Medical Organization

Verification Date

March 2006

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.